Intellia Therapeutics has begun a rolling biologics license application (BLA) for lonvo‑z, its CRISPR‑based gene‑editing therapy for hereditary angioedema (HAE). The rolling submission allows the company to file portions of the application on an ongoing basis, giving the U.S. Food and Drug Administration (FDA) the opportunity to review and provide feedback incrementally, which can accelerate the overall review timeline.
The BLA process is supported by the therapy’s Regenerative Medicine Advanced Therapy (RMAT) designation and participation in the FDA’s CMC Development and Readiness Pilot, both of which streamline regulatory review for advanced therapies. Intellia expects to complete the BLA submission in the second half of 2026 and, if approved, to launch lonvo‑z commercially in the first half of 2027.
Phase 3 results from the HAELO trial, which met its primary endpoint and all key secondary endpoints, demonstrate a significant reduction in HAE attack rates and a high proportion of patients remaining attack‑free and off prophylactic treatment. These data provide the clinical evidence that underpins the BLA and support the claim that lonvo‑z could become the first in‑vivo CRISPR‑based gene‑editing therapy to reach the market.
The potential impact of lonvo‑z extends beyond clinical efficacy. As a one‑time treatment, it offers a paradigm shift from the chronic dosing regimens of current HAE therapies, potentially delivering high gross margins and a strong commercial opportunity in a growing market. The therapy’s unique mechanism—permanent inactivation of the kallikrein B1 gene in hepatocytes—could position Intellia as a leader in the precision‑medicine space and create a new competitive advantage over existing C1 esterase inhibitors, kallikrein inhibitors, and other HAE treatments.
John Leonard, M.D., Intellia’s President and Chief Executive Officer, said, “As the first Phase 3 data reported for an in‑vivo gene editing therapy, today’s HAELO results represent a profound milestone for Intellia, the broader CRISPR and precision medicine fields and, most importantly, the HAE community.” He added that lonvo‑z “offers prolonged freedom from both attacks and the need for ongoing therapy” and that, if approved, it would become the world’s first in‑vivo CRISPR‑based gene‑editing therapy.
Investors reacted positively to the announcement, reflecting confidence in the clinical data and the regulatory pathway. The company’s market position is reinforced by the strong Phase 3 results and the strategic advantage of a one‑time, high‑margin therapy in a niche but expanding market.
Intellia’s next steps include completing the BLA submission in the latter half of 2026 and preparing for a commercial launch in early 2027, positioning the company to capitalize on a first‑mover advantage in the emerging field of in‑vivo gene editing.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.